Evaluation of the diagnostic potential of urinary N-Acetyltyramine-O,β-glucuronide (NATOG) as diagnostic biomarker for Onchocerca volvulus infection by Ole Lagatie et al.
RESEARCH Open Access
Evaluation of the diagnostic potential of
urinary N-Acetyltyramine-O,β-glucuronide
(NATOG) as diagnostic biomarker for
Onchocerca volvulus infection
Ole Lagatie1*, Emmanuel Njumbe Ediage2, Linda Batsa Debrah3, Luc Diels2, Christ Nolten4, Petra Vinken5,
Alex Debrah6, Lieve Dillen2, Steven Silber7 and Lieven J. Stuyver1
Abstract
Background: Onchocerciasis, also known as river blindness is one of the neglected tropical diseases affecting millions
of people, mainly in sub-Saharan Africa and is caused by the filarial nematode Onchocerca volvulus. Efforts to eliminate
this disease are ongoing and are based on mass drug administration programs with the microfilaricide ivermectin. In
order to monitor the efficacy of these programs, there is an unmet need for diagnostic tools capable of identifying
infected patients. We have investigated the diagnostic potential of urinary N-acetyltyramine-O,β-glucuronide
(NATOG), which is a promising O. volvulus specific biomarker previously identified by urine metabolome
analysis.
Methods: A liquid chromatography tandem mass spectrometry (LC-MS/MS) method was used to assess the
stability characteristics of NATOG and to evaluate the levels of NATOG in study samples. An LC-fluorescence
method was also developed.
Results: Stability characteristics of NATOG were investigated and shown to be ideally suited for use in
tropical settings. Also, an easy and more accessible method based on liquid chromatography coupled to
fluorescence detection was developed and shown to have the necessary sensitivity (limit of quantification
1 μM). Furthermore, we have evaluated the levels of NATOG in a population of 98 nodule-positive individuals
from Ghana with no or low levels of microfilaria in the skin and compared them with the levels observed in
different control groups (endemic controls (n = 50), non-endemic controls (n = 18) and lymphatic filariasis
(n = 51). Only a few (5 %) of nodule-positive individuals showed an increased level (> 10 μM) of NATOG and
there was no statistical difference between the nodule-positive individuals and the control groups (P > 0.05).
Conclusions: Results of the present study indicate the limited potential of NATOG as a diagnostic biomarker
for O. volvulus infection in amicrofilaridermic individuals.
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Background
Onchocerciasis, commonly known as river blindness is a
neglected tropical disease caused by infection with the
filarial nematode, O. volvulus. More than 99 % of in-
fected people live in Africa and at least 120 million
people living in these endemic areas are at risk of infec-
tion [1, 2]. The last comprehensive survey conducted in
2008 indicated that 26 million people were infected with
onchocerciasis, of whom 265,000 were blind and 746,000
were visually impaired. In addition, approximately 4
million people suffer from onchodermatitis with severe
itching [3]. Since the introduction of Ivermectin and the
initiation of the mass drug administration programs
(MDA) in 1987, hundreds of millions of people have been
treated with a resultant reduction in both visual impair-
ment and symptomatic onchodermatitis.
Diagnostic tools for detection of O. volvulus infection
traditionally were limited to detection of microfilaria
(mf) in small, superficial skin biopsy samples (skin snips)
[4]. More recently rapid-format tests for the detection of
IgG4 antibodies to the parasitic antigen Ov-16 were de-
veloped [5–10]. Serological antibody tests using recom-
binant antigens however cannot distinguish between
past and active infection. Another shortcoming is their
inability to monitor disease progression or monitor
treatment response. Several efforts have therefore been
undertaken to identify novel biomarkers that do not suf-
fer from these shortcomings [11]. This has already suc-
cessfully been done for Dirofilaria immitis (heartworm)
and Wuchereria bancrofti (the most prevalent cause of
lymphatic filariasis), for which sensitive assays have been
developed that detect circulating filarial antigens in the
blood [12–15]. Also circulating parasitic microRNAs
have been suggested as potential biomarkers for filarial
infection, but it is not clear yet whether this will provide
the required specificity, sensitivity and dynamic range
(for treatment monitoring and determination of cure) to
be useful as diagnostic biomarker for O. volvulus infec-
tion [16–23].
One approach that has shown promise is the use of me-
tabolome analysis of serum samples from infected individ-
uals, but the complexity of the identified set of biomarkers
hampered its further development [24]. Subsequent work
using similar technology, but on urine samples, has identi-
fied urinary N-acetyltyramine-O,β-glucuronide (NATOG)
as a unique biomarker for O. volvulus infection [25]. This
molecule is a neurotransmitter-derived secretion molecule
from O. volvulus.
In the work presented here we have further investi-
gated the potential of NATOG as a diagnostic marker by
evaluating several features. A liquid chromatography
tandem mass spectrometry (LC-MS/MS) method was
optimized and used for all preliminary investigations and
also for the analysis of study samples. First, its stability
under conditions resembling real-life conditions in a
tropical environment as well as adsorption characteris-
tics was investigated. We have also investigated the use
of LC-fluorescence for detection of NATOG in urine,
which would open the path for development of a micro-
fluidic point-of-care device. Furthermore, NATOG levels
in urine samples collected from nodule-positive individ-
uals in Ghana, but with no or very low levels of microfil-
aria in the skin, were assessed and compared to several
control groups in order to determine the diagnostic per-
formance of this biomarker.
Methods
NATOG reference material
N-acetyltyramine-O,β-glucuronide (NATOG) was syn-
thesized by WuXi AppTec Co., Ltd (Hong Kong, China).
Purity and structure were determined by LC-MS, 1H-
NMR and SFC and confirmed to be > 98 % NATOG.
Product was dissolved in Milli-Q water for further use.
Collection of human urine samples
Urine samples were collected as part of a field study in
Ghana. This study was undertaken in an onchocerciasis-
endemic community located in Adansi South District
along the Pra river basins in the Ashanti Region of
Ghana. This study was approved by the Committee on
Human Research, Publications and Ethics of the School
of Medical Sciences of the Kwame Nkrumah University
of Science and Technology, Kumasi, Ghana and study
subjects signed an informed consent form. Physical ex-
aminations were performed to identify those subjects
having palpable nodules. Skin snips (biopsies) were then
taken from those with nodules in order to determine the
microfilarial (mf) load in the skin [26]. Most subjects
were participating in mass drug administration pro-
grams. A total of 98 nodule-positive subjects that do-
nated urine samples were included, as well as 50
endemic controls that had no visible signs of onchocer-
ciasis. Additionally, urine samples from 18 non-endemic
controls (from Kumasi, Ashanti Region) and 51 lymphatic
filariasis patients (from Ahanta West District, Western
Region) were available for testing. An overview of the pa-
tient demographics is provided in Table 1.
Sample preparation
For preparation of calibration samples, Quality Control
(QC) samples and stability samples, urine samples were
obtained from normal healthy subjects in Belgium. Sam-
ples were blinded and no link to the different donors
was maintained. All calibration, QC and stability samples
were prepared by spiking aqueous stock solutions of
NATOG to Milli-Q water or human urine, as indicated.
For investigation of spike recovery of NATOG using the
LC-Fluorescence assay, urine samples collected from
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healthy subjects were used [27–31]. Before analysis, study
samples were diluted 30-fold in Milli-Q water for LC-MS/
MS analysis or 10-fold for LC-Fluorescence analysis.
LC-MS/MS Analysis
The samples (2-μl injection volume) were chromato-
graphically separated using an UPLC (Acquity UPLC;
Waters Corporation, Etten-Leur, Nederland) system on
Acquity HSS T3 column (1.8 μm, 2.1 mm × 50 mm; Wa-
ters Corporation) and analyzed with a Triple quadrupole
MS/MS (API 4000, AB Sciex). The column temperature
was maintained at 45 °C. Eluting buffers were buffer A
(0.1 % HCOOH in H2O) and buffer B (MeOH). Starting
conditions were 2 % buffer B at a flow rate of 0.6 ml/
min. Over 3 min a gradient was applied to 15 % B.
Thereafter the percentage of buffer B was increased to
98 % in a step gradient, followed by an isocratic hold for
0.9 min before returning to the starting conditions. Data
were collected using SRM in positive ESI mode with Q1
Mass 356.1 Da and Q3 Mass 180.1 Da at a dwell time of
100 ms. The capillary voltage was 2,500 V; the nebulizer
pressure, drying gas flow and gas temperature were set
to 20 psig, 7 l/min, and 500 °C, respectively. A linear re-
gression curve was calculated after log-log transform-
ation, based on the data of the calibration samples and
used for determination of NATOG concentration in un-
known samples. Calculations were performed using Ana-
lyst 1.6.2 (Sciex).
LC-Fluorescence Analysis
Analysis was similar to the LC-MS/MS analysis except for
the detector type which in this case was a Waters 474
fluorescence detector (Waters Corporation). The gradient
was slightly adapted to separate co-eluting peaks which
would otherwise result in quenching of the NATOG sig-
nal: starting conditions were 10 % buffer B at a flow rate
of 0.6 ml/min. After 3 min the percentage of buffer B was
increased to 98 % in a step gradient, followed by an iso-
cratic hold for 0.9 min before returning to the starting
conditions. The fluorescence detection wavelengths were
set at λex/λem = 232/290. A linear regression curve was
calculated based on the data of the calibration samples
and used for determination of NATOG concentration in
unknown samples. Calculations were performed using
Empower 3 (Waters Corporation).
Acquisition of 2D fluorescence spectra
The 2D fluorescence spectra of NATOG solutions, urine
and milli-Q water were obtained with a Tecan Infinite
M1000 fluorimeter. The excitation source was a Xenon
Flash lamp, and the detector was a gated photomultiplier.
Double monochromators with selectable bandwidth were
used on both excitation and emission sides. Excitation and
emission slits were 2.5 and 5 nm, respectively. Fluores-
cence spectra were generated in the range 230 to 300 nm
(excitation) and 280 to 350 nm (emission), with an excita-
tion and emission wavelength incrementing step of 2 nm.
Table 1 Demographic information of study population investigated
Characteristic Group
Nodule positive Endemic controls Non-endemic controls Lymphatic filariasis
No. of subjects 98 50 18 51
Age, median (Min-Max) 47 (21–85) 35 (18–81) 25 (13–52) 33 (18–68)
Gender, n (%)
Male 53 (53) 25 (50) 12 (67) 37 (73)
Female 45 (47) 25 (40) 6 (33) 14 (27)
No. of nodules, median (Min-Max) 1 (1–5) 0 na na
mf status, n (%)
0 mf/mg 87 (89) 50 (100) na na
0–5 mf/mg 10 (9) 0 (0) na na
5–10 mf/mg 1 (1) 0 (0) na na
No. of IVM rounds, median (Min-Max) 2 (0–10) 0 (0–1) na na
Time since last ivermectin treatment, n (%) na
Not treated 17 (17) 33 (66) na na
< 20 months 67 (68) 5 (10) na na
> 20 months 14 (14) 12 (24) na na
Ov16 status, n (%)
Positive 68 (69) 25 (50) 0 (0) 12 (24)a
Negative 30 (31) 25 (50) 18 (100) 38 (75)
aFor one LF subject, no Ov16 status has been determined
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Adsorption, temperature and light stability evaluation of
NATOG
The stability of NATOG in different pH (pH 4, 6 and 8)
and temperature conditions (4 °C, room temperature
and 50 °C) for a 24 h period were evaluated with spiked
blank urine samples (spiked with 5.63 μM NATOG).
Possible adsorption onto glass and polypropylene recipi-
ents was evaluated using the same spiked urine samples.
Urine was spiked (in replicate), vortexed and the content
was completely poured into another tube. This cycle was
repeated 5 more times (six tubes in total). The concentra-
tion in tube 1 and 6 were used to determine the amount
adsorbed. For the light (in)stability test, a suntester
(SUNTEST CPS+, Atlas MTS) was used. Samples were in-
cubated in clear and amber glass recipients for 0.5 and 3 h
at 500 W light intensity. Incubation in the suntester for
5 min corresponds to 1 h direct sunlight exposure.
Urinary creatinine measurement
Urinary creatinine was measured by an enzymatic method
on a Cobas® 6000 c 501 clinical chemistry analyzer (Roche
Diagnostics, Mannheim, Germany) using Roche reagents.
Statistical analysis
For comparison of different groups, one-tailed Mann-
Whitney U test and ROC analysis were performed using
GraphPad Prism version 6.02. P-value < 0.05 was consid-
ered to be significantly different.
Results
Performance characteristics of LC-MS/MS assay for
NATOG quantification in urine
In order to assess the levels of NATOG in human urine,
a UPLC-MS/MS method was setup. Calibration curves
were prepared both in Milli-Q water and two different
urine batches (Fig. 1a). All curves showed excellent lin-
ear regression, with R2-values > 0.999. Whereas the blank
sample prepared in milli-Q water showed no signal at
the expected analyte (NATOG) retention time, the blank
samples prepared with human urine, showed a signal
corresponding to low levels of NATOG (0.31 μM and
0.07 μM), indicating that NATOG is present also in
urine from healthy individuals, but at low levels. An ex-
ample chromatogram of the urine sample with endogen-
ous NATOG concentration of 0.31 μM is presented in
Fig. 1b. Quality Control (QC) samples were prepared by
spiking NATOG in urine and milli-Q water at 3 different
levels: 2 μM (QC-Low), 10 μM (QC-Medium) and
50 μM (QC-High). These QC samples were analyzed in
8-fold in order to assess accuracy and precision of the
assay (Table 2). Both accuracy and precision were excel-
lent with accuracy ranging between 96.9 and 112 % and
coefficient of variation (CV) lower than 5 % for all sam-
ples tested.
Evaluation of NATOG stability and adsorption
characteristics
Since samples collected in the field might experience ex-
posure to heat and extensive sunlight, a stability study
was performed to assess the stability of NATOG under
different storage conditions. Results clearly indicate that
NATOG is stable for at least 24 h at 50 °C (under differ-
ent pH conditions) and when exposed to sunlight (3 h in
suntestester, corresponding to approximately 36 h of
sunlight) (Table 3). As samples are stored in glass or
polypropylene (PP) containers, it was investigated
whether NATOG adsorbs to these materials. The data
presented in Table 3 indicate that this is not the case. It
should be noted that the urine sample used for storage
stability and adsorption tests had a background NATOG
concentration of 5.13 μM.
Performance characteristics of LC-Fluorescence assay for
NATOG quantification in urine
Although the simple chromatographic separation used in
the LC-MS/MS assay has the potential to be translated into
a point-of-care microfluidic method, the use of mass spec-
trometry for detection would limit its applicability in
a field setting. We therefore investigated the possibil-
ity of using UPLC followed by fluorescence detection.
Chromatographic conditions were taken from the estab-
lished LC-MS/MS method with slight modification in the
chromatographic gradient (see Methods). Detection was
performed on a Waters 474 fluorescent detector with ex-
citation and emission wavelengths at 232 nm and 290 nm,
respectively. No quenching was observed at 232/290,
whereas for 270/290, quenching of the NATOG signal
was observed at 2 μM (results not shown). Hence, 232/
290 was selected for further sample analysis. Calibration
curves were prepared in Milli-Q water and QC samples
were prepared in Milli-Q water and urine. Calibration
curve showed a nice linear regression (Fig. 1c). Analysis of
the QC samples at the different concentrations demon-
strated that any interfering compounds present in urine
have been separated by the applied chromatography, as
comparable concentrations were obtained both in water
and urine (Table 4). However, it must be noted that at
lower levels (2 μM and 10 μM) slightly higher concentra-
tions were found in urine compared to water, which is
caused by an endogenous NATOG level of 0.31 μM in the
urine sample used for preparation of QC samples, as de-
termined before in the LC-MS experiments.
In order to evaluate the NATOG levels in healthy sub-
jects using the LC-Fluorescence assay, a set of 44 urine
samples collected from normal healthy volunteers was
analyzed (Fig. 2). The majority of subjects had urinary
NATOG levels below the quantification limit of 1 μM
NATOG and only 36 % of subjects had quantifiable
NATOG levels. All but one subject had levels below
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5 μM, while one sample had a NATOG concentration of
7.9 μM. As the fluorescent detection of NATOG can be
impacted by co-eluting quenchers, all samples were also
analyzed after spiking at a final concentration of 50 μM
NATOG. After correction for the endogenous NATOG
levels, all samples were found to contain NATOG levels
of 48–52 μM NATOG, indicating low variability and ex-
cellent accuracy using fluorescence detection.
Assessment of NATOG levels in urine from nodule-positive
subjects and controls
In order to assess the potential of NATOG as biomarker
for diagnosis of O. volvulus infection or treatment
monitoring, we analyzed, using LC-MS/MS, a series of
urine samples from O. volvulus infected subjects and en-
demic controls. Two additional sample sets were in-
cluded to evaluate the NATOG levels in non-endemic
controls and lymphatic filariasis patients. The obtained
data are provided in Additional file 1 and summarized in
Fig. 3a. Most of the O. volvulus infected subjects had very
low levels of NATOG in their urine, with an average value
of 1.06 ± 0.16 μM (± SEM). Only two infected subjects
were identified with NATOG> 5 μM. Furthermore, there
was no significant difference between the infected group
and endemic controls (0.95 ± 0.18 μM) (Mann–Whitney
U test: P = 0.43). Also lymphatic filariasis patients and
Fig. 1 a UPLC-MS/MS Calibration curves of NATOG prepared in water and urine. b UPLC-MS/MS chromatogram of a urine sample with an
endogenous NATOG concentration of 0.31 μM. c LC-Fluo Calibration curve of NATOG prepared in water
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non-endemic controls had similar NATOG levels with an
average value of 0.99 ± 0.17 μM and 0.66 ± 0.18 μM, re-
spectively. Further examination showed there was no sig-
nificant difference between samples from Ov-16-positive
individuals and Ov-16-negative individuals either (Mann–
Whitney U test: P = 0.23, Fig. 3b).
Since urine volume can highly vary upon water con-
sumption, environmental factors and physiological or
pathological factors, metabolite concentrations in urine
also may vary widely [32]. Biomarker concentrations are
therefore commonly expressed as a ratio to the urinary
creatinine concentration. We therefore measured cre-
atinine levels in all urine samples and normalized the
NATOG results based on the corresponding creatinine
value. These normalized data are presented in Fig. 3c.
Although some differences can be observed compared to
the non-normalized data, there still is no statistical dif-
ference between any of the groups investigated. ROC
analysis on the normalized data of nodule-positive and
non-endemic controls (the groups that differ the most),
also indicate that urinary NATOG is not a powerful bio-
marker for discriminating both groups, even after
normalization (AUROC = 0.54, Fig. 3d).
Discussion
Previous work by Globisch et al. [25] found N-acetyltyr-
amine-O,β-glucuronide (NATOG) in urine as a unique
biomarker for O. volvulus infection. We have further in-
vestigated the diagnostic utility of this biomarker and
evaluated its use in field conditions in predominantly
rural settings in sub-Saharan Africa. Essential for this is
the stability of the metabolite at elevated temperatures
and upon extensive sunlight exposure. We found that
NATOG has well-acceptable stability characteristics with
stability in urine being demonstrated upon incubation at
50 °C for 24 h and exposure to extensive light equivalent
Table 3 Stability and adsorption characteristics of NATOG.
Concentrations were obtained after spiking. Samples were
analyzed in duplicate. Accuracy of 80–120 % on the theoretical
spiked concentration was considered acceptable
NATOG μM
Stabilitya Ref. 24 h 4 °C 24 h RT 24 h 50 °C
Urine pH 4 11.0 ± 0.3 10.7 ± 0.0 11.0 ± 0.4 10.9 ± 0.0
Urine pH 6 10.9 ± 0.3 11.2 ± 0.1 11.4 ± 0.0 11.7 ± 0.1
Urine pH 8 11.6 ± 0.3 11.6 ± 0.1 11.6 ± 0.2 11.8 ± 0.1
Sun stabilityb Ref. 0.5 h Suntest 3 h Suntest
Clear vials 2.65 ± 0.01 2.61 ± 0.03 2.57 ± 0.01
Amber vials 2.64 ± 0.01 2.65 ± 0.01 2.61 ± 0.03
Adsorption testa Ref. glass 6 cycles glass Ref. PP 6 cycles PP
Urine pH 4 10.5 ± 0.3 11.0 ± 0.1 10.7 ± 0.1 10.8 ± 0.1
Urine pH 6 11.2 ± 0.1 11.1 ± 0.1 10.7 ± 0.8 11.1 ± 0.1
Urine pH 8 11.3 ± 0.1 11.4 ± 0.1 11.5 ± 0.1 11.3 ± 0.0
aUrine with an endogenous NATOG concentration of 5.13 μM was spiked with
5.63 μM NATOG
bSample of 2.81 μM NATOG in Milli-Q water
Abbreviations: Ref. reference, RT room temperature, PP Polypropylene
Table 2 Accuracy and precision of the detection of NATOG using UPLC-MS/MS (n = 8)
QC-Low (2 μM) QC-Medium (10 μM) QC-High (50 μM)
Milli-Q Water
Mean 2.12 10.8 48.5
Standard deviation 0.07 0.40 0.39
Coefficient of variation (%) 3.5 3.7 0.8
% Accuracy 106 108 96.9
Human urine
Mean 2.23 11.0 55.1
Standard deviation 0.07 0.35 2.32
Coefficient of variation (%) 3.3 3.2 4.2
% Accuracya 112 110 110
aEndogenous level of NATOG used for preparation of QC samples was 0.31 μM; results have not been corrected for the endogenous levels
Table 4 Accuracy and precision of the detection of NATOG








Mean 2.03 10.2 52.3
Standard deviation 0.02 0.34 1.94
Coefficient of variation (%) 1.0 3.3 3.7
% Accuracy 102 102 105
Human urine
Mean 2.31 10.3 52.2
Standard deviation 0.08 0.17 0.56
Coefficient of variation (%) 3.5 1.7 1.1
% Accuracya 115 103 104
aEndogenous level of NATOG used for preparation of QC samples was
0.31 μM; results have not been corrected for the endogenous levels
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to 36 h sunlight. Also no adsorption was observed to
glass or polypropylene tubes. These characteristics
would ease collection of samples from remote areas and
transportation to a central lab for analysis of urinary
NATOG. However, although centralized analyses are
possible, not many local laboratories have access to LC-
MS/MS capabilities. We have therefore developed an
LC-Fluorescence method for quantification of NATOG
in urine. On the one hand, this technology is more read-
ily available in those regions, but on the other hand it
also opens the path for development of microfluidic
tools that could then be used for point-of-care assess-
ment of NATOG. We have shown here that fluorescent
detection preceded by simple chromatographic separ-
ation is feasible and does not require any extraction
procedure. This offers the possibility to convert this LC-
Fluorescence assay into a simple test consisting of a micro-
fluidic chromatography system coupled to fluorescence
Fig. 2 NATOG levels in urine from healthy volunteers from Belgium,
both non-spiked and spiked with 50 μM NATOG. NATOG levels were
analyzed with the LC-Fluorescence assay. Recovered NATOG is
calculated by subtracting the endogenous level (non-spiked) from
the total (spiked) concentration
Fig. 3 a Urinary NATOG levels in urine from nodule-positive individuals in Ghana, endemic controls, non-endemic controls and lymphatic filariasis
patients. b Comparison of urinary NATOG levels between Ov-16-positive and Ov-16-negative individuals. c Normalized NATOG levels using urinary
creatinine for normalization. d ROC analysis based on the normalized NATOG levels in nodule-positive individuals and non-endemic controls
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detector using a laser or light emitting diode (LED) as the
excitation light source [33, 34].
In the last part of our investigation, we evaluated the
diagnostic accuracy of urinary NATOG as biomarker for
O. volvulus infection. In this sample set, collected from
Ghana, we could not detect significantly elevated levels
(> 20 μM) in urine from infected subjects. Most samples
had NATOG levels below 5 μM. Only two samples out
of 98 appeared to have slightly elevated levels of
NATOG with 12 μM being the highest level observed,
which was still far from the previously observed concen-
trations that reached levels above 100 μM in some indi-
viduals. Also, when compared to the levels in urine from
non-infected controls (both endemic and non-endemic),
no statistical difference could be observed since also in
these subjects urinary NATOG levels up till 5 μM were
found. Furthermore, also in one of the urine batches that
were used for preparation of the stability samples and
that were donated by healthy volunteers from Belgium,
5 μM NATOG was detected. All these observations to-
gether can be summarized in two main conclusions: (i)
non-infected individuals usually have very low levels of
urinary NATOG, but under certain circumstances, these
levels might slightly increase; and (ii) in nodule-positive
subjects from Ghana no clearly elevated levels of urinary
NATOG can be detected. Since urine can be more or less
diluted, we also examined the data after normalization
with urinary creatinine. It is assumed that urinary
creatinine excretion rate is constant within an individ-
ual over time and across individuals, and that bio-
marker production or excretion has a linear relationship
with urinary creatinine excretion across individuals [35].
Normalization of the data however did not affect any of
the conclusions.
One explanation for the discrepancy between these
and previous observations might be the fact that in this
study all nodule-positive subjects are from a community
that participates in a mass drug administration program
and maybe more importantly, all subjects had no or very
low levels of microfilaria detected in the skin. It is likely
that an active infection, with clear microfilaridermic fea-
tures, is required for urinary NATOG to increase to a
level that differs significantly from the levels in unin-
fected individuals. This would still value NATOG as a
biomarker for O. volvulus infection, but more specifically
to identify microfilaridermic patients with active infec-
tion and to be able to monitor treatment efficacy in
them. In this respect, it should be noted that in previous
work also samples were included from infected patients
who were treated with ivermectin or ivermectin and doxy-
cycline [25]. Remarkably, ivermectin treatment alone did
not result in a reduction of urinary NATOG levels while
treatment with doxycycline (and ivermectin) did cause a
dramatic drop in the NATOG levels in urine samples,
collected 20 months after treatment. Whereas ivermectin
has direct microfilaricidal activity, doxycycline kills the
endosymbiotic bacteria Wolbachia, thereby sterilizing the
adult female worm, ultimately also resulting in a reduced
microfilarial load [36–40]. Detailed analysis of the samples
that were used in this assessment however, demonstrated
that in the group treated only with ivermectin, a substan-
tial amount of microfilaria are still present in the skin
while no or very low numbers were detected in the group
treated with doxycycline and ivermectin [41]. This obser-
vation supports the hypothesis that urinary NATOG is in-
deed elevated in case of active infection with substantial
levels of microfilaria in the skin. This hypothesis is further
supported by the fact that the samples used in this study
were collected along the Pra River, in an area that has
been shown to have no active onchocerciasis transmission.
This is caused by the ceased blackfly breading due to the
high water turbidities in the river, caused by the intensifi-
cation of the gold-digging activities along the river [42].
This would imply that all nodule-positive individuals have
older adult worms (>3 years) which are shown to be
morphologically and immunohistologically different from
younger worms [43]. These older worms often are found
to be senescent with empty uteri, signs of degeneration
and in some cases already might have died, also as a result
of consecutive rounds of ivermectin treatment [43, 44]. It
is very likely to assume that these older worms produce
much lower levels of tyramine compared to their younger
and more active counterparts.
An alternative explanation for the different observa-
tions is the possibility that NATOG is not, or not only
produced as a result of O. volvulus infection but is in
fact the result of the metabolism of tyramine absorbed
from the gut. Although Globisch and coworkers
indicated that tyramine acetylation, the first step in the
metabolism of tyramine to NATOG, is specifically per-
formed by O. volvulus enzymes before being secreted
into the host for further metabolism and excretion, it is
well possible that this acetylation step is performed by a
host liver enzyme or by enzymes in the gastrointestinal
mucosa [25, 45, 46]. Consequently, increased levels of
tyramine in the gut, either directly from food or after
production by gut bacteria, may result in increased urin-
ary NATOG levels. In this respect, it is well-known that
tyramine is adsorbed in the body upon consumption of
e.g. fermented cheese and wine, with Enterococcus faeca-
lis being one of the most important bacteria producing
tyramine in fermented food products [47–51]. It is
however not clear whether this could lead to the
very high levels (> 100 μM) that were observed in
O. volvulus-infected individuals [25]. Further re-
search will be required to better characterize the ori-
gin of NATOG in urine and to elucidate the role the
gut flora might play.
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Conclusions
Our data show that urinary NATOG as a diagnostic bio-
marker for O. volvulus infection appears not to be useful
in patients with very low levels of microfilaria in the skin
and indicate that NATOG most likely can only be used
as biomarker of a highly productive infection of O. vol-
vulus. More studies where urinary NATOG is measured
in patients with different levels or stages of infection will
be required to confirm these conclusions.
Additional file
Additional file 1: Overview of data obtained for all samples (urinary
NATOG, urinary creatinine and Ov16 status). (XLSX 18 kb)
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